Tetra Bio-Pharma readies Canadian launch of THC medicine for chemotherapy relief

The product named Reduvo will treat chemotherapy-induced nausea and vomiting.

Patients undergoing chemotherapy may find relief from a prescription medicine with synthetic THC. AndreaObzerova/Getty Images

0

Tetra Bio-Pharma Inc. looks on track to deliver a medicine for cancer patients who are going through chemotherapy.

The Orleans, Ontario-based company hopes to soon release Reduvo, a cannabinoid-derived medication.

Tetra says the prescription drug is designed to treat chemotherapy-induced nausea and vomiting or CINV.

The generic name of the medicine is dronabinol.

It is marketed in other countries like the U.S. under the brand name Marinol.

Dronabinol is a synthetic or manmade form of tetrahydrocannabinol or THC, the main psychoactive compound found in the cannabis plant.

A 2018 guide released by Health Canada noted that Marinol is no longer available in the country.

In the same paper, the agency noted that pre-clinical studies show that certain cannabinoids or compounds in the cannabis plant like THC “suppress acute nausea and vomiting as well as anticipatory nausea”.

“Clinical studies suggest that certain cannabinoids and cannabis (limited evidence) use may provide relief from chemotherapy-induced nausea and vomiting (CINV),” Health Canada stated.

Moreover, CINV is “one of the most distressing and common adverse events associated with cancer treatment”.

“In the absence of effective anti-emetics, chemotherapy-associated nausea can be so severe that as many as 20% of patients opt to discontinue chemotherapeutic treatment,” the federal agency noted.

In a media release Tuesday (October 5), Tetra noted that Health Canada is “currently in its final stage” of reviewing the company’s Reduvo medicine.

The company projects gross sales of $121 million in Canada from 2022 to 2026.

Reduvo will come in the form of a soft gel capsule.

Tetra indicated in a June 2, 2021 media release that it anticipates that the medicine will be “publicly and privately reimbursed by provinces and Canadian private healthcare plans”.

The company trades in the Toronto Stock Exchange under the ticker symbol TBP.

As of this post, each Tetra share was trading at $0.27 each.

Follow Carlito Pablo on Twitter at @carlitopablo

Leave your opinion for the editor...We read everything!

Your email address will not be published. Required fields are marked *